Accelerate Diagnostics logo

Accelerate DiagnosticsNASDAQ: AXDX

Profile

Sector:

Healthcare

Country:

United States

IPO:

07 April 1994

Next earnings report:

09 August 2024

Last dividends:

N/A

Next dividends:

N/A
$27.63 M
-94%vs. 3y high
27%vs. sector
-vs. 3y high
-vs. sector
-67%vs. 3y high
10%vs. sector
-95%vs. 3y high
40%vs. sector

Price

after hours | Fri, 28 Jun 2024 21:42:32 GMT
$1.17+$0.02(+1.74%)

Dividend

No data over the past 3 years
$2.92 M$3.01 M
$2.92 M-$14.23 M

Analysts recommendations

Institutional Ownership

AXDX Latest News

Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research02 May 2024 Sentiment: NEGATIVE

Accelerate Diagnostics (AXDX) lacks the necessary elements for a potential earnings surprise in its upcoming report. Be ready for the expected results.

Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript
Seeking Alpha28 March 2024 Sentiment: POSITIVE

Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript

Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research28 March 2024 Sentiment: NEGATIVE

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $1.40 per share a year ago.

Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
Zacks Investment Research29 November 2023 Sentiment: POSITIVE

Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.

Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research22 November 2023 Sentiment: POSITIVE

Accelerate Diagnostics (AXDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?
Zacks Investment Research03 October 2023 Sentiment: POSITIVE

Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research10 August 2023 Sentiment: NEGATIVE

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $2.36 per share versus the Zacks Consensus Estimate of a loss of $1.50. This compares to loss of $2.40 per share a year ago.

Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research29 June 2023 Sentiment: NEUTRAL

Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.

Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
Zacks Investment Research23 May 2023 Sentiment: POSITIVE

Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.

Accelerate Diagnostics, Inc. (AXDX) Q1 2023 Earnings Call Transcript
Seeking Alpha11 May 2023 Sentiment: POSITIVE

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Laura Pierson - Investor Relations Jack Phillips - President & Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good day, and welcome to the Accelerate Diagnostics Incorporated 2023 Q1 Results Conference Call. All participants will be in listen-only mode.

What type of business is Accelerate Diagnostics?

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

What sector is Accelerate Diagnostics in?

Accelerate Diagnostics is in the Healthcare sector

What industry is Accelerate Diagnostics in?

Accelerate Diagnostics is in the Medical Devices industry

What country is Accelerate Diagnostics from?

Accelerate Diagnostics is headquartered in United States

When did Accelerate Diagnostics go public?

Accelerate Diagnostics initial public offering (IPO) was on 07 April 1994

What is Accelerate Diagnostics website?

https://acceleratediagnostics.com

Is Accelerate Diagnostics in the S&P 500?

No, Accelerate Diagnostics is not included in the S&P 500 index

Is Accelerate Diagnostics in the NASDAQ 100?

No, Accelerate Diagnostics is not included in the NASDAQ 100 index

Is Accelerate Diagnostics in the Dow Jones?

No, Accelerate Diagnostics is not included in the Dow Jones index

When does Accelerate Diagnostics report earnings?

The next expected earnings date for Accelerate Diagnostics is 09 August 2024